Carl June, M.D.
Carl June, M.D. is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine and is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine. He is also Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. Carl has published more than 500 manuscripts and is the recipient of numerous honors, including election to the National Academy of Medicine, the National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society.
Kole Roybal, Ph.D.
Kole Roybal, Ph.D. is an Associate Professor in the Department of Microbiology and Immunology at the University of California, San Francisco. He is currently a member of the Parker Institute for Cancer Immunotherapy, the Helen Diller Family Comprehensive Cancer Center, and an inaugural Chan Zuckerberg Biohub Investigator. He is also the Deputy Director of the UCSF Center for Synthetic Immunology recently funded by the Cancer Moonshot Initiative. Kole was awarded the Sartorius and Science Magazine Prize for Regenerative Medicine and Cell Therapy and the NIH New Innovator Award in 2018. His body of work was foundational to the next-generation immune cell therapy company, Cell Design Labs, where he was a founding scientist. Cell Design Labs was acquired by Gilead at the end of 2017.
Steven A. Feldman, Ph.D.
Steven Feldman, Ph. D. has more than 20 years of experience as a leader in cell and gene therapy space and is currently the Site Head and Scientific Director for Stanford’s Laboratory of Cell and Gene Medicine, the Stanford GMP Facility where he leads process development and manufacturing efforts to ensure the safe administration of engineered T cell therapy products in support of Stanford Investigator-Initiated and Industry-sponsored clinical trials. Prior to this, Steven was a member of the Surgery Branch, National Cancer Institute (NCI). He established the Surgery Branch Vector Production Facility and manufactured more than 20 clinical-grade viral vector products to support Surgery Branch clinical trials. In addition, he participated in the development and transfer of one of the first commercial CD19-directed CAR-T cell therapies.
Matthew Porteus, M.D., Ph.D.